Relevant bibliographies by topics / Benralizumab

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers
  5. Reports

Academic literature on the topic 'Benralizumab'

Author: Grafiati
Published: 14 March 2023
Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Benralizumab.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Benralizumab"

1

Pini, Laura, Diego Bagnasco, Bianca Beghè, et al. "Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study." Journal of Clinical Medicine 13, no. 10 (2024): 3013. http://dx.doi.org/10.3390/jcm13103013.

Full text
Abstract:
Background: Benralizumab has been shown to restore good control of severe eosinophilic asthma (SEA). Robust data on benralizumab effectiveness over periods longer than 2 years are scarce. Methods: This retrospective multicentric study was conducted on 108 Italian SEA patients treated with benralizumab for up to 36 months. Partial and complete clinical remission (CR) were assessed. Data were analyzed with descriptive statistics or using linear, logistic, and negative binomial mixed-effect regression models. Results: At 36 months, benralizumab reduced the exacerbation rate by 89% and increased t
APA, Harvard, Vancouver, ISO, and other styles
2

Malakauskas, Kęstutis, Kristina Biekšienė, Marius Zolubas, et al. "Benralizumabo veiksmingumas gydant sunkia eozinofiline astma sergančius pacientus. BREEZE tyrimo Lietuvos duomenys." Pulmonology and allergology 8, no. 2 (2024): 175–80. http://dx.doi.org/10.37499/pia.1486.

Full text
Abstract:
Retrospektyvusis benralizumabo tyrimas BREEZE, skirtas apibūdinti pacientų savybes, gydymo būdus ir rezultatus klinikinėje praktikoje Vidurio Rytų Europos ir Baltijos šalyse, yra tarptautinės programos XALOC dalis. Daugiacentrių Lietuvos klinikinės praktikos tyrimų duomenų, gydant sergančiuosius sunkia eozinofiline astma benralizumabu, nėra. Tikslas. Įvertinti benralizumabo veiksmingumą klinikinėje praktikoje, gydant sunkia eozinofiline astma sergančius pacientus Lietuvoje. Tyrimo metodai. Šiame tyrime aprašomi Lietuvos pacientų, dalyvavusių BREEZE tyrime, duomenys. Į tyrimą įtraukti suaugę pa
APA, Harvard, Vancouver, ISO, and other styles
3

Miguel Reyes, José Luis, Erika del Carmen López Estrada, Monserrat Arroyo Rojas, et al. "Benralizumab in severe eosinophilic asthma: A real-world, single-center, observational study from Mexico." Allergologia et Immunopathologia 51, no. 6 (2023): 8–15. http://dx.doi.org/10.15586/aei.v51i6.852.

Full text
Abstract:
Introduction: Urbanization has increased the prevalence of asthma in lower- and middle-income countries. Severe eosinophilic asthma (SEA), a subtype of asthma, can be refractory to standard therapy. Biologics such as benralizumab target interleukin-5 and have demonstrated effectiveness in managing SEA. There exists no real-world evidence on the effectiveness of benralizumab in Mexico. Therefore, this study presents data on the role of benralizumab in managing SEA in Mexican patients. Objective: The effectiveness of benralizumab on the quality of life (QoL), asthma control, lung function, sympt
APA, Harvard, Vancouver, ISO, and other styles
4

Antoniu, S. A. "Benralizumab." Drugs of the Future 39, no. 7 (2014): 463. http://dx.doi.org/10.1358/dof.2014.039.07.2156125.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Antoniu, S. A. "Benralizumab." Drugs of the Future 39, no. 7 (2014): 463. http://dx.doi.org/10.1358/dof.2014.39.7.2156125.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sandhu, Yuuki, Norihiro Harada, Hitoshi Sasano, et al. "Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma." Biomolecules 13, no. 3 (2023): 538. http://dx.doi.org/10.3390/biom13030538.

Full text
Abstract:
Benralizumab treatment reduces exacerbations and improves symptom control and quality of life in patients with severe eosinophilic asthma. However, the determination of biomarkers that predict therapeutic effectiveness is required for precision medicine. Herein, we elucidated the dynamics of various parameters before and after treatment as well as patient characteristics predictive of clinical effectiveness after 1 year of benralizumab treatment in severe asthma in a real-world setting. Thirty-six patients with severe asthma were treated with benralizumab for 1 year. Lymphocyte subsets in peri
APA, Harvard, Vancouver, ISO, and other styles
7

Zhuravleva, M. V., S. N. Avdeev, Yu V. Gagarina, and T. V. Marin. "Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings." FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 15, no. 2 (2022): 175–86. http://dx.doi.org/10.17749/2070-4909/farmakoekonomika.2022.143.

Full text
Abstract:
Objective: evaluation of the pharmacoeconomic feasibility of using benralizumab in the form of autoinjector (pen-injector device) in outpatient facilities compared with its use in the form of a syringe in hospital settings for the treatment of severe asthma (SA).Material and methods. The cost minimization and budget impact analysis methods were used. The current practice of treating patients with SA with benralizumab in hospital settings at the expense of compulsory medical insurance funds was compared with the simulated practice. The simulated price was calculated as half patients receiving b
APA, Harvard, Vancouver, ISO, and other styles
8

Shnaider, К. О., M. L. Maksimov, and S. А. Martynova. "Efficacy and safety of benralizumab." Glavvrač (Chief Medical Officer), no. 10 (October 12, 2024): 31–46. http://dx.doi.org/10.33920/med-03-2410-03.

Full text
Abstract:
The purpose of the review is to analyze Russian and foreign literature sources on the effectiveness and safety of benralizumab in the treatment of moderate and severe bronchial asthma. Benralizumab is a humanized monoclonal antibody directed against the interleukin-5 receptor (IL-5R) subunit. Binding of benralizumab with the alpha chain of IL-5R leads to inhibition of hetero-oligomerization of alpha and beta subunits, thus preventing signal transduction and consequent proliferation of eosinophils and basophils and the cascade of events following it. Benralizumab significantly reduces annual as
APA, Harvard, Vancouver, ISO, and other styles
9

Bourdin, Arnaud, Don Husereau, Nicolas Molinari, et al. "Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review." European Respiratory Journal 52, no. 5 (2018): 1801393. http://dx.doi.org/10.1183/13993003.01393-2018.

Full text
Abstract:
Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal antibody that directly depletes eosinophils. Its relative efficacy versus other IL-5-targeted treatments for patients with severe, uncontrolled asthma is not yet fully characterised.We performed a matching-adjusted indirect comparison (MAIC) of benralizumab versus mepolizumab and reslizumab. Trials were selected through systematic review and evaluation of trial methods. Benralizumab patient-level data were weighted to match treatment-effect-modifying patient characteristics of comparator trials before indirect efficacy c
APA, Harvard, Vancouver, ISO, and other styles
10

Menzella, Francesco, Mariarita Marchi, Marco Caminati, et al. "Long-Term Eosinophil Depletion: A Real-World Perspective on the Safety and Durability of Benralizumab Treatment in Severe Eosinophilic Asthma." Journal of Clinical Medicine 14, no. 1 (2024): 191. https://doi.org/10.3390/jcm14010191.

Full text
Abstract:
Background/Objectives: Benralizumab is an anti-IL-5 receptor alpha monoclonal antibody that induces the near-complete depletion of eosinophils. This study aimed to evaluate the long-term safety and effectiveness of benralizumab in patients with severe eosinophilic asthma (SEA) over an extended 48-month follow-up period, offering one of the longest real-world perspectives available. Methods: This was a single-arm, retrospective, observational, multicenter study involving 123 SEA patients treated with benralizumab at a dosage of 30 mg every 4 weeks for the first 3 doses and then every 8 weeks. T
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Benralizumab"

1

Laura, Bergantini. "Immune modulatory effects of novel monoclonal antibodies target therapies in severe eosinophilic asthma patients." Doctoral thesis, Università di Siena, 2020. http://hdl.handle.net/11365/1120137.

Full text
Abstract:
New anti IL-5 antibodies, mepolizumab and benralizumab, have recently been approved for severe asthma, sharing the same inclusion criteria. To contribute on biomarkers research leading to the personalized choice, we investigated L-selectin, KL-6 and lymphocyte subsets as bioindicators of airways hyper-responsiveness and remodelling and to phenotype patients according to their answer to the treatment. L‐selectin mediates leukocyte rolling of lung endothelium and its expression on T cells is increased in asthma patients. Regulatory T cells (Tregs) suppress inflammation by secreting a wide variet
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Benralizumab"

1

"Benralizumab." In Encyclopedia of Molecular Pharmacology. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-57401-7_300078.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pico Freire, X., T. González Furelos, R. Ruíz Ferreras, M. Granero López, I. Rodríguez Legazpi, and I. Rodríguez Penín. "COMPARATIVA DE EFECTIVIDAD DE MEPOLIZUMAB, BENRALIZUMAB Y DUPILUMAB EN ASMA GRAVE NO CONTROLADA." In Libro de comunicaciones 69 Congreso SEFH. Sociedad Española de Farmacia Hospitalaria, 2024. http://dx.doi.org/10.62917/24.69.0156.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Varela Fernández, Rubén, Eva Martínez Álvarez, Juan Carlos Sáez Hortelano, et al. "Resultados en salud de benralizumab en el tratamiento del asma eosinofílica grave no controlada." In Libro de comunicaciones 69 Congreso SEFH. Sociedad Española de Farmacia Hospitalaria, 2024. http://dx.doi.org/10.62917/24.69.0140.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

MORALES RIVERO, BEGOÑA, AINHOA PLAZA ARBEO, VANESA CAO VIÑA, and ALVARO JOSE MORENO LOPEZ. "BENRALIZUMAB: EFECTIVIDAD E INFLUENCIA DEL TABAQUISMO Y OBESIDAD EN EL CONTROL DEL ASMA GRAVE EOSINOFILICA." In Libro de comunicaciones 69 Congreso SEFH. Sociedad Española de Farmacia Hospitalaria, 2024. http://dx.doi.org/10.62917/24.69.0624.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Garcia, Fernanda Mariano, Priscila Pinto e. Silva-dos-Santos, Valdemir Pereira de Sousa, et al. "Asma e Medicina de Precisão: Avanços Moleculares e Terapias Personalizadas." In Medicina Personalizada: Genética e Inovações no Tratamento de Doenças. Editora Científica Digital, 2025. https://doi.org/10.37885/250519439.

Full text
Abstract:
A asma é uma condição inflamatória crônica das vias aéreas, caracterizada por heterogeneidade clínica e imunopatológica. A medicina de precisão emerge como um paradigma promissor ao integrar dados genéticos, epigenéticos, moleculares e ambientais para estratificar pacientes em fenótipos e endótipos específicos, promovendo abordagens terapêuticas individualizadas. A distinção entre inflamação tipo 2 (T2-alta), geralmente eosinofílica, e T2-baixa, associada a perfis neutrofílicos ou paucigranulocíticos, tem guiado a aplicação de biomarcadores como eosinofilia periférica, FeNO e IgE específica. T
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Benralizumab"

1

Harrison, T., A. L. Fuhlbrigge, M. Fagerås, et al. "Benralizumab Reduces Asthma Worsening Episodes." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7087.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bleecker, Eugene R., Xingnan Li, Paul Newbold, et al. "Benralizumab treatment and SARP cluster analysis." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa1659.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yang, A., M. Gilani, R. P. Ramonell, and M. Gauthier. "Persistent Lung Eosinophilia While on Benralizumab." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5304.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Singh, D., G. J. Criner, A. Agusti, et al. "Effect of benralizumab on recurrent COPD exacerbations." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.3906.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Samant, M., P. Lyons, and M. Castro. "Benralizumab: Not Just for Your Poorly Controlled Asthmatic." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1355.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Jackson, David J., Tim Harrison, Francesco Menzella, Vivian H. Shih, Annie Burden, and Esther Garcia Gil. "Identifying super-responders to benralizumab in severe asthma." In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa3734.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kontogianni, Chrysoula, Konstantinos Samitas, Petros Bakakos, et al. "Follow-up of patients with severe eosinophilic asthma receiving benralizumab for one year (gReek rEAl Life regIStry of benralizuMab: REALISM Study)." In ERS International Congress 2023 abstracts. European Respiratory Society, 2023. http://dx.doi.org/10.1183/13993003.congress-2023.pa4709.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Marchewski, H., G. Schwefel, K. Bratke, JC Virchow, and M. Lommatzsch. "Benralizumab reduziert Blut-Basophile bei Patienten mit schwerem Asthma." In 61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V. Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0039-3403072.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Newbold, Paul, Hao Liu, Tuyet-Hang Pham, Gautam Damera, and Sriram Sridhar. "Modulation of inflammation by benralizumab in eosinophilic airway disease." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa4902.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Nair, Parameswaran, Manali Mukherjee, Hui Fang Lim, et al. "Benralizumab attenuates airway eosinophilopoietic processes in prednisone-dependent asthma." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.oa3217.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Benralizumab"

1

Zhou, Wen. Does benralizumab effectively treat chronic obstructive pulmonary disease? a protocol of systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.4.0039.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Benralizumab' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography